Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) saw unusually-high trading volume on Monday following a better than expected earnings announcement. Approximately 279,432 shares were traded during trading, a decline of 13% from the previous session's volume of 319,447 shares.The stock last traded at $136.42 and had previously closed at $156.98.
The company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.20 by $0.09. Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on KRYS shares. Guggenheim lowered their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a research report on Friday, July 25th. Citigroup reaffirmed a "neutral" rating and issued a $176.00 target price (up from $155.00) on shares of Krystal Biotech in a research report on Wednesday, July 9th. Bank of America decreased their target price on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research report on Friday, July 25th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Krystal Biotech has a consensus rating of "Buy" and a consensus target price of $211.33.
Read Our Latest Research Report on Krystal Biotech
Insider Buying and Selling
In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the business's stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the completion of the sale, the insider directly owned 1,508,056 shares of the company's stock, valued at approximately $226,208,400. The trade was a 0.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders sold 49,800 shares of company stock worth $7,487,943. Insiders own 13.70% of the company's stock.
Institutional Trading of Krystal Biotech
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fifth Third Bancorp increased its holdings in Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after purchasing an additional 105 shares in the last quarter. GAMMA Investing LLC increased its holdings in Krystal Biotech by 179.3% during the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after purchasing an additional 432 shares in the last quarter. Federated Hermes Inc. increased its holdings in Krystal Biotech by 1.8% during the 4th quarter. Federated Hermes Inc. now owns 13,048 shares of the company's stock worth $2,044,000 after purchasing an additional 229 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Krystal Biotech by 18.7% during the 4th quarter. JPMorgan Chase & Co. now owns 151,835 shares of the company's stock worth $23,786,000 after purchasing an additional 23,934 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its stake in shares of Krystal Biotech by 4.7% in the 4th quarter. Alliancebernstein L.P. now owns 31,120 shares of the company's stock worth $4,875,000 after buying an additional 1,400 shares during the last quarter. 86.29% of the stock is owned by institutional investors.
Krystal Biotech Stock Performance
The business has a 50 day moving average price of $140.83 and a two-hundred day moving average price of $155.89. The stock has a market cap of $3.85 billion, a PE ratio of 32.14 and a beta of 0.70.
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
